Etrasimod

Chemical formula: C₂₆H₂₆F₃NO₃ Molecular mass: 457.186 g/mol PubChem compound: 44623998

Therapeutic indications

Etrasimod is indicated for:

Ulcerative colitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Etrasimod is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once daily

Contraindications

Etrasimod is contraindicated in the following cases:

Pregnancy

Lactation

Immunodeficient state

Immunodeficiency disorder

Patients who in the last 6 months experienced heart failure or stroke

at least one of

Myocardial infarction
Angina
CVA - Cerebrovascular accident
Temporary cerebral vascular dysfunction
Decompensated cardiac failure
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

Atrioventricular block, sick sinus syndrome, sino-atrial block

at least one of

Mobitz type II atrioventricular block
Complete atrioventricular block
Sick sinus syndrome
Sinoatrial block

Severe active infections

Infectious disease

Active malignancies

Malignant tumour

Severe hepatic impairment

Hepatic failure stage IV

Live vaccines

Live organism vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.